Loretta S. Li

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

A. Letai, S. Sallan, M. Harris, 2015, Cancer cell.

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

Gabriela Alexe, Giovanni Roti, Nicola Tolliday, 2012, The Journal of clinical investigation.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16)

J. Rowley, N. Zeleznik-Le, Y. Hayashi, 2004, Genes, chromosomes & cancer.

Rapid identification of BCR/ABL1‐like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time‐polymerase chain reaction: clinical, prognostic and therapeutic implications

O. Elemento, R. Foà, S. Chiaretti, 2018, British journal of haematology.

Polymorphisms in the MLL breakpoint cluster region (BCR)

S. Raimondi, M. Relling, J. Rowley, 2003, Human Genetics.

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

W. Hahn, K. Ross, J. Aster, 2012, The Journal of clinical investigation.